VBIV (VBI Vaccines, Inc.) מחיר חזוי לרווח

סמלים רשמיים של חברת VBI Vaccines, Inc. (VBIV)

VBI Vaccines Inc. minimizes operational risks through an extensive network of external research centers. The brand's scientific authority is confirmed by the development of an innovative hepatitis B vaccine. The company's estimated forward P/E on GURU.Markets captures valuation dynamics, where 0.00 serves as the current metric level. The business's financial stability is based on government contracts and commercial drug sales.

VBIV - שווי שוק לרווח חזוי vbivaccines.com בטווח 04.07.2022 - 17.08.2024

פילוחים אנליטיים של חברת VBI Vaccines Inc.

- מדדי הערכת שווי שוק של העסק:
ניתוח בסיסי של החברה:VBI Vaccines Inc VBIV
דוגמת מוצר של VBI Vaccines Inc.

For the biotech business of VBI Vaccines Inc. (VBIV) with high R&D expenditures, the company's forward P/E ratio serves as an indicator of market expectations for future earnings. The ratio of the current share price to the projected EPS allows for an assessment of the discount or premium, accounting for the high operating leverage that is activated during the transition from vaccine development to mass low-cost production.